Mail Sport's racing expert Robin Goodfellow delivers his tips for Saturday's meetings at Southwell, Newcastle, Ascot, Wincanton and Haydock. Southwell Robin Goodfellow 4.05 Jesse Luc 4.40 Blue ...

Mail Sport's racing expert Robin Goodfellow delivers his tips for Wednesday's meetings at Sandown, Newcastle, Leicester and Chelmsford City. ROBIN GOODFELLOW 1.20 Casa Loupi 1.55 MOUNT TEMPEST ...

Barclays analyst Gena Wang maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $329.00. The company’s shares closed yesterday at $264.89.

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to $250M for litifilimab, a first-in-class ...

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...

DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

MILAN, Feb. 12, 2025 /PRNewswire/ -- DOC, an Italian pharmaceutical company specialized in the marketing of generic drugs, expands its strategy by broadening its business lines and defines a new ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

- Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ...

– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE ...

The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024. Net cash used in operating activities was approximately $60.9 million, compared to $102.0 million ...

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group.